Company Overview of Ther-Rx Corporation
Ther-Rx Corporation engages in the development and marketing of specialty women’s healthcare products. It offers Makena, a prescription hormone medicine (progestin) and a hydroxyprogesterone caproate injection that is used to lower the risk of preterm birth in women who are pregnant with one baby and who have delivered one baby too early (preterm) in the past; and Clindesse, a single-dose treatment for non-pregnant women with bacterial vaginosis. The company also provides Evamist (estradiol transdermal spray), an estrogen spray to reduce moderate-to-severe hot flashes caused by menopause; and Gynazole-1 vaginal cream to offer relief in to non-pregnant women with vulvovaginal candidiasis. In ...
One Corporate Woods Drive
Bridgeton, MO 63044
Founded in 1998
Key Executives for Ther-Rx Corporation
Compensation as of Fiscal Year 2014.
Ther-Rx Corporation Key Developments
Ther-Rx Corporation Announces Availability of Treatment for Bacterial Vaginosis
Aug 15 13
Ther-Rx Corporation has announced the availability of Clindesse Vaginal Cream, 2% indicated for the treatment of bacterial vaginosis in non-pregnant women.
Ther-Rx Corporation and Perrigo Co. Announce the Availability of Gynazole-1 (Butoconazole Nitrate Vaginal Cream Usp, 2%) for Prescribing
Jan 24 13
Ther-Rx Corporation and Perrigo Co. announced that Gynazole-1 (Butoconazole Nitrate Vaginal Cream USP, 2%), indicated for the local treatment of yeast infections (vulvovaginal candidiasis infections caused by Candida) in non-pregnant women, is now available for prescribing. Gynazole-1 is available at major national and regional retail pharmacy chains across the country. Ther-Rx has partnered with Perrigo to manufacture Gynazole-1. Perrigo is a manufacturer of prescription drugs in the U.S. market that has been inspected and approved by the U.S. Food and Drug Administration (FDA) as being in compliance with current Good Manufacturing Practice requirements to manufacture Gynazole-1. Gynazole-1 (Butoconazole Nitrate Vaginal Cream USP, 2%) is indicated for the local treatment of vulvovaginal candidiasis (infections caused by Candida). The diagnosis should be confirmed by KOH smears and/or cultures.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries